Background Colistin–carbapenem combinations are synergistic in vitro against carbapenem-
resistant Gram-negative bacteria. We aimed to test whether combination therapy improves …

Objectives In vitro models showing synergism between polymyxins and carbapenems
support combination treatment for carbapenem-resistant Gram-negative (CRGN) infections …

Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …

ABSTRACT A retrospective cohort study evaluated the effectiveness and nephrotoxicity of
intravenous colistin monotherapy vs. colistin–meropenem combination therapy for patients …

ABSTRACT A retrospective case series study was performed in a 30-bed general intensive
care unit (ICU) of a tertiary care hospital to assess the effectiveness and safety of colistin in …

Colistin is commonly the last resort for treatment of infections caused by multidrug-resistant
Gram-negative bacteria. In clinical practice, it is frequently used as combination therapy in …

It is unclear whether the effectiveness of polymyxins depends on the site of infection, the
responsible pathogen, dosage, and monotherapy vs. combination therapy. We investigated …

Background. Colistin is increasingly used for the treatment of multidrug-resistant gram-
negative infections. However, colistin dosing varies greatly and the optimal regimen is …

Background Colistin has re-entered clinical use by necessity. We aimed to assess its
effectiveness and safety compared with newer antibiotics. Methods This was a single-centre …

Carbapenem-resistant Acinetobacter baumannii (CRAB), an important nosocomial
pathogen, occurs particularly in the intensive care unit (ICU). Thus, the aim of this study was …